For thousands of breast cancer patients, the completion of neoadjuvant therapy brings relief, yet a lingering uncertainty remains. Will the cancer return? Traditional imaging often misses microscopic disease, leaving clinicians and patients guessing during the critical surveillance window. A shift toward molecular monitoring is changing this paradigm, offering a clearer view of recurrence risk through […]
You can read the full story here: <![CDATA[Circulating Tumor DNA After Neoadjuvant Therapy Predicts Breast Cancer Recurrence]]> .